Background And Aims: Primary liver cancer (PLC) ranks among of the most common cancers worldwide. Within this group, a minority of cases displays characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), known as combined hepatocellular cholangiocarcinoma (cHCC- CCA). Currently, there is no specific standardized therapy for these mixed tumors. Therefore, the aim of our study was to analyze the clinical course, treatment and outcome of cHCC-CCA patients in a European population-based registry.
Methods: We investigated 9,144 patients with PLC (6,622 HCC, 2,356 iCCA, and 166 cHCC-CCA) diagnosed between 2009 and 2020. All data were obtained from Clinical Cancer Registry of Baden-Württemberg (BW), Germany.
Results: In all three groups patients were predominantly male (82%, 57%, and 68% for HCC, iCCA and cHCC-CCA groups, respectively). 48% of cHCC-CCA patients were diagnosed as stage IV cancers, which was more than for HCC (31%) but less compared to CCA (64%). Overall median survival of cHCC-CCA patients was worse compared to HCC (9-13 months vs. 15.5 months, p<0.001) and rather comparable to CCA (11.8 months).
Conclusions: Our data demonstrated that cHCC-CCA tumors appear to have a distinct clinical course with worse overall survival compared to HCC. Thus, identification of these cancers by histopathology is essential in order to further characterize this tumor entity and to provide accurate treatment to these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.15403/jgld-4893 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The correlation between contrast-enhanced ultrasound Liver Imaging Reporting and Data System classification and differentiation grades of combined hepatocellular carcinoma-cholangiocarcinoma.
Quant Imaging Med Surg
January 2025
Department of Medical Ultrasound, West China Hospital of Sichuan University, Chengdu, China.
Background: The contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) classification offers a framework for risk stratification in evaluating liver lesions in patients at risk for hepatocellular carcinoma (HCC). However, its clinical utility in combined HCC-cholangiocarcinoma (cHCC-CCA) has been less extensively studied. The degree of tumor differentiation is clinically significant in determining prognosis, making the analysis of imaging features across different differentiation levels essential.
View Article and Find Full Text PDFClinicopathologic and ultrasonographic features of combined hepatocellular-cholangiocarcinoma and its correlation with microvascular invasion: a predictive role of contrast-enhanced ultrasound.
Front Oncol
December 2024
Clinical Medical College, Guizhou Medical University, Guiyang, Guizhou, China.
Article Synopsis
- The study investigates the characteristics of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and its association with microvascular invasion (MVI) using ultrasonography, particularly contrast-enhanced ultrasound (CEUS).
- A retrospective analysis of 57 patients with cHCC-CCA found that those with MVI exhibited specific ultrasonographic features, such as larger tumor size and distinct CEUS patterns.
- Results indicated that features like low echo halo, irregular rim-like enhancement, and early washout are significant risk factors for MVI, providing a predictive tool for clinicians.
Prognostic Impact of CCA Components in Combined Hepatocellular Carcinoma-Cholangiocarcinoma.
J Hepatocell Carcinoma
December 2024
Department of Radiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, People's Republic of China.
Purpose: To investigate the differences of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) patients with a cholangiocarcinoma (CCA) component ≥ 30% or < 30% versus intrahepatic cholangiocarcinoma (iCCA) patients in recurrence-free survival (RFS) and overall survival (OS) prognoses.
Methods: Patients with cHCC-CCA and iCCA after surgery were recruited. All cHCC-CCA patients were divided into two subgroups (CCA components ≥ 30% and < 30%).
Radiomics predicting immunohistochemical markers in primary hepatic carcinoma: Current status and challenges.
Heliyon
December 2024
Department of Intervention, Shenzhen People's Hospital, Shenzhen, 518020, Guangdong, China.
Primary hepatic carcinoma, comprising hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined hepatocellular cholangiocarcinoma (cHCC-CCA), ranks among the most common malignancies worldwide. The heterogeneity of tumors is a primary factor impeding the efficacy of treatments for primary hepatic carcinoma. Immunohistochemical markers may play a potential role in characterizing this heterogeneity, providing significant guidance for prognostic analysis and the development of personalized treatment plans for the patients with primary hepatic carcinoma.
View Article and Find Full Text PDFPersistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion.
Mol Cancer
December 2024
Key Laboratory of Birth Defects and Related Diseases of Women and Children, West China Second University Hospital, Ministry of Education, Sichuan University, Chengdu, 610041, Sichuan, P.R. China.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA), an extremely rare and underinvestigated subtype of primary liver cancer in children, generally has a poor prognosis and greater aggressiveness. Histological diagnosis of cHCC-CCA is difficult because of its diverse components, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). cHCC-CCA shares some genetic alterations with HCC and CCA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!